As of 2025-09-18, the Relative Valuation of Cymabay Therapeutics Inc (CBAY) is (16.45) USD. This relative valuation is based on P/E multiples. With the latest stock price at 32.48 USD, the upside of Cymabay Therapeutics Inc based on Relative Valuation is -150.7%.
The range of the Relative Valuation is (15.79) - (17.20) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 15.2x - 18.7x | 17.8x |
| Forward P/E multiples | 17.2x - 19.4x | 18.0x |
| Fair Price | (15.79) - (17.20) | (16.45) |
| Upside | -148.6% - -153.0% | -150.7% |
| Date | P/E |